DELEX

AcronymDefinition
DELEXDestroyer Life-Extension Program (Canada)
References in periodicals archive ?
Therapeutics, reporting to Diana Pliura, CEO of DELEX.
As at December 31, 2006 the Company had 55,782,023 common shares outstanding, 2,380,953 common shares held in escrow for contingent additional payment related to the acquisition of DELEX Therapeutics Inc.
As at September 30, 2006 the Company had 55,782,023 common shares outstanding, 2,380,953 common shares held in escrow for contingent additional payment related to the acquisition of DELEX Therapeutics Inc.
a company engaged in the acquisition, development and commercialization of oncology and acute care products, today announced that its DELEX Therapeutics division has received the results of an interim analysis on the first 67 patients from its randomized, placebo-controlled Phase IIb trial (DLXLEF-AP4) of AeroLEF(TM) for the treatment of moderate to severe acute pain in post-surgical patients.
In May 2005, the Company acquired DELEX Therapeutics Inc.
James Updike will serve as Vice-President and General Manager, DELEX Therapeutics, reporting to Diana Pliura, CEO of DELEX.